PreFIT

PreFit’s aim is to validate diagnostic prediction assays used at point-of-care.

Objective

PreFit’s objectives aim to validate diagnostic prediction assays used at point-of-care.


Description

PreFIT aims to validate assays for improved prediction of progression from latent tuberculosis infection (LTBI) to active tuberculosis (TB) disease. Assays with high positive predictive value (PPV) for progression to TB disease have great potential for reducing TB morbidity and mortality in Africa by allowing scale-up of preventive treatment, which is becoming possible with shorter, safer preventive treatment regimens. PreFIT will achieve high PPV for progression to TB disease with a package of assays that diagnose incipient TB, a stage of LTBI progressing towards disease that can be halted with preventive treatment. These assays test for specific messenger RNA, C-reactive protein and hemoglobin on field-friendly platforms. PreFIT will take the next step in development of these novel and existing assays by validating them prospectively at point-of-care for their clinical performance, feasibility and cost in a cohort of TB-exposed household contacts.


AIGHD Research Lead

Prof. Frank Cobelens


Partners

Fundacao Manhica, Mozambique

Stellenbosch University, South Africa

Makerere University, Uganda

Fundación Privada Instituto de Salud Global Barcelona (ISGLobal),  Spain

Foundation for Innovative New Diagnostics (FIND), Switzerland


Contact info

Atrjom Tsirelson (a.tsirelson@aighd.org)


Funders

EDCTP2


Countries

Netherlands

Switzerland

Spain

Mozambique

Uganda

South Africa